We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+16.58%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$641M
AUM Growth
+$38.5M
Cap. Flow
-$44.3M
Cap. Flow %
-6.91%
Top 10 Hldgs %
93.46%
Holding
22
New
5
Increased
2
Reduced
10
Closed
1

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$6.89M
2
VRML
Vermillion, Inc.
VRML
+$1.08M
3
AQB icon
AquaBounty Technologies
AQB
+$171K
4
NXTM
NxStage Medical Inc.
NXTM
+$7.46K

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$36.9M
2
AXDX
Accelerate Diagnostics
AXDX
+$7.15M
3
AMRN
Amarin Corp
AMRN
+$3.84M
4
PGEN icon
Precigen
PGEN
+$2.97M
5
AGEN
Agenus
AGEN
+$874K

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.32%
3 Consumer Staples 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$157M 24.5%
1,021,475
-226,611
-18% -$36.9M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$114M 17.81%
471,953
-31,286
-6% -$7.15M
MZOR
3
DELISTED
Mazor Robotics Ltd.
MZOR
$80.7M 12.59%
2,711,842
-8,100
-0.3% -$191K
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
$73M 11.39%
2,721,906
+270
+0% +$7.46K
QDEL icon
5
QuidelOrtho
QDEL
$808M
$57M 8.89%
2,517,554
– –
PACB icon
6
Pacific Biosciences
PACB
$404M
$28.5M 4.44%
5,506,732
-10,162
-0.2% -$49.7K
OPK icon
7
Opko Health
OPK
$1.17B
$28.3M 4.41%
3,533,000
-1,539
-0% -$13K
AMRN
8
Amarin Corp
AMRN
$291M
$21.5M 3.36%
336,307
-60,443
-15% -$3.84M
BIOL
9
DELISTED
Biolase, Inc.
BIOL
$19.7M 3.08%
1,170
– –
VRML
10
DELISTED
Vermillion, Inc.
VRML
$19.3M 3.01%
9,241,956
+617,731
+7% +$1.08M
PGEN icon
11
Precigen
PGEN
$2.45B
$13.8M 2.15%
694,902
-133,073
-16% -$2.97M
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$8.87M 1.38%
+516,940
New +$6.89M
ARAY icon
13
Accuray
ARAY
$29.9M
$6.74M 1.05%
1,418,194
-72,685
-5% -$379K
AGEN
14
Agenus
AGEN
$312M
$6.44M 1%
87,093
-11,033
-11% -$874K
CFRX
15
DELISTED
ContraFect Corporation
CFRX
$2.13M 0.33%
1,478
– –
BIIB icon
16
Biogen
BIIB
$32.1B
$1.74M 0.27%
6,368
-355
-5% -$100K
TSRO
17
CALL
DELISTED
TESARO, Inc.
TSRO
$1.58M 0.25%
+350,000
New +$57M
AXDX
18
CALL
DELISTED
Accelerate Diagnostics
AXDX
$475K 0.07%
+10,000
New +$2.28M
AQB icon
19
AquaBounty Technologies
AQB
$6.28M
$135K 0.02%
+610
New +$171K
VANI icon
20
Vivani Medical
VANI
$115M
$61K 0.01%
2,117
– –
NXTM
21
CALL
DELISTED
NxStage Medical Inc.
NXTM
$20K ﹤0.01%
+100,000
New +$2.76M
TCRT icon
22
Alaunos Therapeutics
TCRT
$3.84M
– –
-44
Closed -$36K

Similar funds

EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM
CWA
Clearview Wealth Advisors Salem, Oregon $158M AUM 14.25% 1-Year Est. Return
CNFG
Creegan & Nassoura Financial Group Portsmouth, New Hampshire $154M AUM 17.18% 1-Year Est. Return
VA
Verus Advisory Seattle, Washington $153M AUM
PSB
Passumpsic Savings Bank St. Johnsbury, Vermont $183M AUM

Oracle Investment Management's Q1 2017 Portfolio in Review

As of Q1 2017, Oracle Investment Management held 22 positions worth $641M, up 6.4% from $603M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Oracle Investment Management withdrew a net $44.3M in Q1 2017, closing 1 position and reducing 10 holdings. Its most notable exit was Alaunos Therapeutics, an estimated $36K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Oracle Investment Management opened a new position in Epizyme, Inc worth $8.87M.

  • Oracle Investment Management's largest Q1 2017 buy was Epizyme, Inc: 516,940 shares worth $8.87M.
  • Oracle Investment Management added most to Vermillion, Inc. in Q1 2017, an estimated $1.08M increase.
  • Oracle Investment Management's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $36.9M.
  • Oracle Investment Management fully exited Alaunos Therapeutics in Q1 2017, selling an estimated $36K.
  • Oracle Investment Management's ten largest holdings make up 93% of its $641M portfolio in Q1 2017.
  • Oracle Investment Management opened 5 new positions and closed 1 in Q1 2017.
  • Oracle Investment Management's portfolio value rose 6.4% quarter-over-quarter to $641M.

Based on Oracle Investment Management's 13F filing for Q1 2017, filed 15 May 2017.